Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen

Cancer

Volumn 94, Issue 2, 2002, Pages 285-291

  Weiser, Mary A ^a,b   O'Brien, Susan ^a   Thomas, Deborah A ^a   Pierce, Sherry A ^a   Lam, Tony P ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphocytic leukemia (ALL); And dexamethasone) chemotherapy; Doxorubicin; Filgrastim; Granulocyte colony stimulating factor (G CSF).; Hyper CVAD (cyclophosphamide; Vincristine

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MEPREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFECT; FEMALE; HUMAN; INFECTION RISK; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; PRIORITY JOURNAL; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PLATELET COUNT; REMISSION INDUCTION; VINCRISTINE;

EID: 0037080259     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10241     Document Type: Article

References (17)

1. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology group study (9031)
2. Granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022
3. A randomized controlled trial of filgastrim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111
4. Randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
5. Granulocyte colony-stimulating factor (filgrastim, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: Effects, role of patient pretreatment characteristics and costs
6. Delaying treatment with granulocyte colony stimulating factor after allogeneic bone marrow transplant for hematologic malignancies: A prospective randomized trial
7. A prospective randomized trial of Filgrastim (r-metHufilgrastim) given at different times after unrelated bone marrow transplantation
8. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation
9. Influence of rhfilgrastim scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice
10. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy
11. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult lymphocytic leukemia
12. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions
13. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans
14. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity
15. Responses to granulocyte colony-stimulating factor (filgrastim) and granulocyte-macrophage CSF in Ph'-positive acute lymphoblastic leukemia with myeloid surface markers
16. Frequent gene expression of granulocyte colony-stimulating factor (filgrastim) receptor in CD7+ surface CD3-acute lymphoblastic leukemia
17. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia